Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?

Of the 17 participants with MPR (57%), median DFS was 34.5 months compared with 14.3 months in those without MPR, but this did not reach statistical significance.

also in 111,027 other papers